SELPLG and melanoma: PSGL-1–deficient Selplg−/− mice were found to have stronger immune responses as evidenced by significantly decreased tumor burden in a syngeneic melanoma model and improved viral clearance with increased proinflammatory cytokine release and less exhausted T cells in a chronic viral infection model (23).